Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 8/20 | 0.43 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293659 | 0.93 | HTR2C (0.45) | HTR2CMAOBCFTRNR2E1PTGDR2 | |
| SCHEMBL2298363 | 0.86 | ANO1 (0.46) | HRH3EDNRAMEN1KMT2A | |
| SCHEMBL2294694 | 0.84 | MAPT (0.47) | MEN1KMT2A | |
| SCHEMBL2295379 | 0.84 | NR1H4 (0.47) | NR2E1PTGDR2EDNRAMEN1KMT2A | |
| SCHEMBL2295598 | 0.83 | MEN1 (0.43) | MEN1KMT2A | |
| SCHEMBL2296917 | 0.83 | SMN1; SMN2 (0.39) | MEN1KMT2A | |
| SCHEMBL2294478 | 0.83 | NPC1 (0.48) | MEN1KMT2A | |
| SCHEMBL2298688 | 0.82 | NPC1 (0.48) | MEN1KMT2A | |
| SCHEMBL2294479 | 0.82 | FADS1 (0.46) | — | |
| SCHEMBL2297504 | 0.82 | FFAR1 (0.48) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | HTR2C 4544/4885MAOB 4454/4885CFTR 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.